Elimination of Hepatitis C Virus Infection Among Hemodialysis Patients Will Be Possible If All Patients Undergo Treatment

AUTHORS

Seyed Moayed Alavian 1 , *

1 Baqiyatallah Research Center for Gastroenterology and Liver Diseases, Baqiyatallah University of Medical Sciences, Tehran, Iran

How to Cite: Alavian S M. Elimination of Hepatitis C Virus Infection Among Hemodialysis Patients Will Be Possible If All Patients Undergo Treatment, Int J Infect. 2018 ; 5(4):e69025. doi: 10.5812/iji.69025.

ARTICLE INFORMATION

International Journal of Infection: 5 (4); e69025
Published Online: October 13, 2018
Article Type: Letter
Received: April 2, 2018
Accepted: October 7, 2018
Crossmark

Crossmark

CHEKING

READ FULL TEXT

Keywords

Hepatitis C Hepatitis B Hemodialysis

Copyright © 2018, International Journal of Infection. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.

Dear Editor,

I recently read with interest the published article by Ibrahim et al. (1). Hepatitis C virus (HCV) infection is associated with high mortality among patients undergoing hemodialysis (2). The prevalence of HCV infection among hemodialysis patients is varied in different countries, and a meta-analysis on Iraqi patients undergoing hemodialysis reported a prevalence of 20% for HCV infection (3); however, the prevalence of this disease seems to be lower in Kurdish region compared to other parts of Iraq. Control of HCV infection, as a health hazard, is necessary in hemodialysis patients. In the study by Ibrahim et al. (1), all HCV-infected patients had history of transfusion, but 16 out of 87 patients who were HCV negative did not have history of transfusion. I believe that the limited number of HCV-infected patients avoiding the authors from concluding that transfusion history was a risk factor. Transfusion history has been considered as a cardinal risk factor in several studies and I suggest to use other modalities for the management of anemia in these patients. It is worth mentioning that duration of hemodialysis is another risk factor that the authors did not address in their study. If we seeking to follow the ultimate goal of the World Health Organization for the elimination of HCV infection in our community, it will be easier to do so in hemodialysis patients using validated strategies, the most important of which being treatment of all infected patients. In so doing, the vicious cycle of nosocomial transmission due to poor infection control measures will be halted.

For the management of hepatitis B virus (HBV) infection, periodic screening of HBs Ag, separation of devices and location of hemodialysis centers, vaccination against HBV infection, follow up for anti-HBs antibody, and devising new strategies for better response to HBV vaccination in this high-risk group are suggested (4).

References

  • 1.

    Ibrahim NMR, Sidiq Mohammed Saleem Z, R Hussein N. The prevalence of HIV, HCV, and HBV among hemodialysis patients attending duhok hemodialysis center. Int J Infect. 2017;5(1). e63246. doi: 10.5812/iji.63246.

  • 2.

    Kargar Kheirabad A, Bahri F, Kargar M, Ghasemzadeh I. Hepatitis C and G virus infection prevalence among hemodialysis patients and associated risk factors in the Hormozgan province of Southern Iran. Hepat Mon. 2016;16(10). e40375. doi: 10.5812/hepatmon.40375. [PubMed: 27882069]. [PubMed Central: PMC5111419].

  • 3.

    Ashkani-Esfahani S, Alavian SM, Salehi-Marzijarani M. Prevalence of hepatitis C virus infection among hemodialysis patients in the Middle-East: A systematic review and meta-analysis. World J Gastroenterol. 2017;23(1):151-66. doi: 10.3748/wjg.v23.i1.151. [PubMed: 28104991]. [PubMed Central: PMC5221279].

  • 4.

    Fabrizi F, Maria Donato F, Messa P. Efficacy and safety of reinforced versus standard vaccine schedule towards hepatitis b in chronic kidney disease: A systematic review and meta-analysis. Hepat Mon. 2017;17(7). e44179. doi: 10.5812/hepatmon.44179.

  • COMMENTS

    LEAVE A COMMENT HERE: